筋骨格系疾患のジェネリック医薬品の世界市場レポート 2025年

筋骨格系疾患のジェネリック医薬品の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR（複合年間成長率）7.2％で8,000万米ドルに成長します。予測期間の成長は、人口増加と高齢化、新興市場、精密医療と個別化治療、ヘルスケア改革、世界のヘルス動向に起因すると考えられます。予測期間における主な動向には、治療における技術統合、政府の取り組みとヘルスケア政策、疼痛管理代替薬への注目、バイオシミラーの採用増加、ジェネリック医薬品開発の進展などがあります。

関節炎の著しい蔓延は、今後数年間の筋骨格系疾患のジェネリック医薬品市場の成長を牽引すると予想されます。関節炎は関節の圧痛や腫れを伴い、関節痛やこわばりなどの症状を伴います。筋骨格系疾患のジェネリック医薬品は、筋肉の痛みやこわばりを緩和するように設計されており、関節炎患者の筋肉の痙攣を効果的に治療することができます。例えば、2022年3月、英国を拠点とする慈善団体Versus Arthritisが発表したデータによると、英国では約1,000万人が変形性関節症と診断されており、その内訳は膝関節OAが540万人、股関節OAが320万人です。さらに、約45万人が関節リウマチ、19万人が乾癬性関節炎を患っており、2,000万人以上が筋骨格系の疾患を抱えていることになります。その結果、2022～2023年にかけて、これらの疾患のために3,000万以上の処方箋が発行され、約1億3,900万英ポンドの費用となりました。したがって、関節炎の高い有病率が筋骨格系疾患のジェネリック医薬品市場の成長に拍車をかけています。

遠隔医療の採用拡大が筋骨格系疾患のジェネリック医薬品市場の成長をさらに促進すると予想されます。遠隔医療は、通信とデジタル技術を活用して遠隔ヘルスケアサービスを提供するもので、患者と医療提供者の間の仮想診察を促進します。遠隔医療を導入することにより、筋骨格系疾患の患者に対するアクセスのしやすさ、利便性、ケアの継続性が向上します。例えば、2023年4月にFAIR Health Inc.が発表したデータによると、全国的な遠隔医療の利用は7.3%増加し、2022年12月の医療費請求行の5.5%から2023年1月には5.9%に上昇しました。このように、遠隔医療の普及は筋骨格系疾患のジェネリック医薬品市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の筋骨格系疾患のジェネリック医薬品市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の筋骨格系疾患のジェネリック医薬品市場：成長率分析
• 世界の筋骨格系疾患のジェネリック医薬品市場の実績：規模と成長、2019～2024年
• 世界の筋骨格系疾患のジェネリック医薬品市場の予測：規模と成長、2024～2029年、2034年
• 世界の筋骨格系疾患のジェネリック医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の筋骨格系疾患のジェネリック医薬品市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬剤
• 療法
• 手術
• その他
• 世界の筋骨格系疾患のジェネリック医薬品市場：疾患の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 変形性関節症
• 関節リウマチ
• 脊椎関節炎
• 若年性特発性関節炎
• 乾癬性関節炎
• 線維筋痛症
• その他
• 世界の筋骨格系疾患のジェネリック医薬品市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• その他
• 世界の筋骨格系疾患のジェネリック医薬品市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• ドラッグストア
• オンライン薬局
• 世界の筋骨格系疾患のジェネリック医薬品市場：薬剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非ステロイド性抗炎症薬（NSAID）
• 鎮痛剤
• コルチコステロイド
• 疾患修飾性抗リウマチ薬（DMARD）
• 生物製剤
• 世界の筋骨格系疾患のジェネリック医薬品市場：療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 理学療法
• 作業療法
• カイロプラクティック
• マッサージセラピー
• 世界の筋骨格系疾患のジェネリック医薬品市場：手術のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 関節置換手術
• 関節鏡検査
• 脊椎手術
• 固定手術
• 世界の筋骨格系疾患のジェネリック医薬品市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 生活習慣の見直し
• 代替療法
• 補助器具

第7章 地域別・国別分析

• 世界の筋骨格系疾患のジェネリック医薬品市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の筋骨格系疾患のジェネリック医薬品市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 筋骨格系疾患のジェネリック医薬品市場：競合情勢
• 筋骨格系疾患のジェネリック医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Ampio Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Merck & Co. Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• AstraZeneca plc
• Mitsubishi Tanabe Pharma Corporation
• Horizon Therapeutics plc
• Eisai Co. Ltd.
• Biogen Inc.
• Sino Biopharmaceutical Limited
• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 筋骨格系疾患のジェネリック医薬品市場2029年：新たな機会を提供する国
• 筋骨格系疾患のジェネリック医薬品市場2029年：新たな機会を提供するセグメント
• 筋骨格系疾患のジェネリック医薬品市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Generic musculoskeletal disorders drugs play a crucial role in managing conditions related to the musculoskeletal system, providing relief from pain, stiffness in muscles, and treating muscle spasms.

The main treatments for generic musculoskeletal disorders drugs include medication, therapy, surgery, and other interventions. Medications come in various forms, containing one or more active chemicals and potential inactive components. They can be administered through oral, parenteral, and other routes to address conditions such as osteoarthritis, rheumatoid arthritis, spondylarthritis, juvenile idiopathic arthritis, psoriatic arthritis, fibromyalgia, and other musculoskeletal disorders. These drugs are distributed through different channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The generic musculoskeletal disorders drugs market research report is one of a series of new reports from The Business Research Company that provides generic musculoskeletal disorders drugs market statistics, including generic musculoskeletal disorders drugs industry global market size, regional shares, competitors with a generic musculoskeletal disorders drugs market share, detailed generic musculoskeletal disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic musculoskeletal disorders drugs industry. This generic musculoskeletal disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The generic musculoskeletal disorders drugs market size has grown strongly in recent years. It will grow from $0.06 billion in 2024 to $0.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to incidence of musculoskeletal disorders, regulatory environment, healthcare infrastructure development, patient awareness and education, economic factors.

The generic musculoskeletal disorders drugs market size is expected to see strong growth in the next few years. It will grow to $0.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to population growth and aging, emerging markets, precision medicine and personalized therapies, healthcare reforms, global health trends. Major trends in the forecast period include technological integration in treatment, government initiatives and healthcare policies, focus on pain management alternatives, increased adoption of biosimilars, advancements in generic drug development.

The significant prevalence of arthritis is anticipated to drive the growth of the generic musculoskeletal disorders drugs market in the coming years. Arthritis involves tenderness and swelling of the joints, accompanied by symptoms such as joint pain and stiffness. Generic musculoskeletal disorders drugs are designed to alleviate pain and stiffness in muscles and can effectively treat muscle spasms in arthritis patients. For instance, in March 2022, data published by Versus Arthritis, a UK-based charity, indicated that approximately 10 million individuals in the UK are diagnosed with osteoarthritis, which includes 5.4 million with knee OA and 3.2 million with hip OA. Additionally, around 450,000 people have rheumatoid arthritis and 190,000 have psoriatic arthritis, contributing to over 20 million individuals living with musculoskeletal conditions. This has resulted in more than 30 million prescriptions dispensed for these conditions at a cost of about £139 million in 2022-2023. Therefore, the high prevalence of arthritis is fueling the growth of the generic musculoskeletal disorders drugs market.

The increasing adoption of telemedicine is expected to further propel the growth of the generic musculoskeletal disorders drugs market. Telemedicine involves leveraging telecommunications and digital technologies to provide remote healthcare services, facilitating virtual consultations between patients and healthcare providers. The adoption of telemedicine enhances accessibility, convenience, and continuity of care for patients with musculoskeletal disorders. For instance, data from FAIR Health Inc. in April 2023 indicates a 7.3% increase in national telehealth use, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Thus, the growing embrace of telemedicine contributes to the expansion of the generic musculoskeletal disorders drugs market.

Strategic partnerships emerge as a prominent trend in the generic musculoskeletal disorders drugs market, with companies entering partnerships to bolster their market positions. A notable example is the collaboration between Mitsubishi Tanabe Pharma Corporation, a Japanese pharmaceutical company, and Eli Lilly and Company, a U.S.-based pharmaceutical company, aimed at broadening product lines and providing effective treatments for conditions such as diabetes. Additionally, Pfizer Inc., a major pharmaceutical and biotechnology corporation, partnered with Alex Therapeutics, a Swedish digital therapeutics company, in February 2022, offering patients evidence-based, clinically verified, and tailored digital therapeutics through this strategic alliance.

Major companies operating in the generic musculoskeletal disorders drugs market are placing emphasis on innovative products to drive revenue growth. An example is the introduction of the non-permanent ossiofiber compression staple by Ossio Inc., a U.S.-based company specializing in orthopedic and musculoskeletal applications. This medical device, designed for fracture fixation and bone fusion in orthopedic surgeries, offers temporary stability and compression to promote bone healing and fusion. The non-permanent ossiofiber compression staple presents an alternative to traditional implants and permanent metal hardware.

In October 2023, Amgen Inc., a U.S.-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. This acquisition enables Amgen to diversify its product line and offer treatments for severe inflammatory, autoimmune, and rare disorders. Horizon Therapeutics Plc, an Ireland-based biopharmaceutical company, contributes to Amgen's commitment to utilizing biology to address life-threatening disorders.

Major companies operating in the generic musculoskeletal disorders drugs market include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca plc, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Eisai Co. Ltd., Biogen Inc., Sino Biopharmaceutical Limited, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Mylan Pharmaceuticals Inc., Taisho Pharmaceutical Holdings Co. Ltd., Flexion Therapeutics Inc.

Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the generic musculoskeletal disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generic musculoskeletal disorders drugs market consists of sales of analgesics, oral non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-neuropathic pain medications, corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Musculoskeletal Disorders Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic musculoskeletal disorders drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic musculoskeletal disorders drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic musculoskeletal disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medication; Therapy; Surgery; Other Treatment Types
• 2) By Disorder Type: Osteoarthritis; Rheumatoid Arthritis; Spondylarthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Fibromyalgia; Other Disorder Types
• 3) By Route Of Administration: Oral; Parenteral; Other Routes
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Drug Store; Online Pharmacy
• Subsegments:
• 1) By Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Analgesics; Corticosteroids; Disease-Modifying Antirheumatic Drugs (DMARDs); Biologics
• 2) By Therapy: Physical Therapy; Occupational Therapy; Chiropractic Treatment; Massage Therapy
• 3) By Surgery: Joint Replacement Surgery; Arthroscopy; Spinal Surgery; Fusion Surgery
• 4) By Other Treatment Types: Lifestyle Modifications; Alternative Therapies; Assistive Devices
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Eli Lilly and Company; Ampio Pharmaceuticals Inc.; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Musculoskeletal Disorders Drugs Market Characteristics

3. Generic Musculoskeletal Disorders Drugs Market Trends And Strategies

4. Generic Musculoskeletal Disorders Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Generic Musculoskeletal Disorders Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Generic Musculoskeletal Disorders Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Generic Musculoskeletal Disorders Drugs Market Growth Rate Analysis
• 5.4. Global Generic Musculoskeletal Disorders Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Generic Musculoskeletal Disorders Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Generic Musculoskeletal Disorders Drugs Total Addressable Market (TAM)

6. Generic Musculoskeletal Disorders Drugs Market Segmentation

• 6.1. Global Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Therapy
• Surgery
• Other Treatment Types
• 6.2. Global Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Osteoarthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Fibromyalgia
• Other Disorder Types
• 6.3. Global Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.4. Global Generic Musculoskeletal Disorders Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Drug Store
• Online Pharmacy
• 6.5. Global Generic Musculoskeletal Disorders Drugs Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Analgesics
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Biologics
• 6.6. Global Generic Musculoskeletal Disorders Drugs Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Therapy
• Occupational Therapy
• Chiropractic Treatment
• Massage Therapy
• 6.7. Global Generic Musculoskeletal Disorders Drugs Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Joint Replacement Surgery
• Arthroscopy
• Spinal Surgery
• Fusion Surgery
• 6.8. Global Generic Musculoskeletal Disorders Drugs Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lifestyle Modifications
• Alternative Therapies
• Assistive Devices

7. Generic Musculoskeletal Disorders Drugs Market Regional And Country Analysis

• 7.1. Global Generic Musculoskeletal Disorders Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Generic Musculoskeletal Disorders Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Musculoskeletal Disorders Drugs Market

• 8.1. Asia-Pacific Generic Musculoskeletal Disorders Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Musculoskeletal Disorders Drugs Market

• 9.1. China Generic Musculoskeletal Disorders Drugs Market Overview
• 9.2. China Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Musculoskeletal Disorders Drugs Market

• 10.1. India Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Musculoskeletal Disorders Drugs Market

• 11.1. Japan Generic Musculoskeletal Disorders Drugs Market Overview
• 11.2. Japan Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Musculoskeletal Disorders Drugs Market

• 12.1. Australia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Musculoskeletal Disorders Drugs Market

• 13.1. Indonesia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Musculoskeletal Disorders Drugs Market

• 14.1. South Korea Generic Musculoskeletal Disorders Drugs Market Overview
• 14.2. South Korea Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Musculoskeletal Disorders Drugs Market

• 15.1. Western Europe Generic Musculoskeletal Disorders Drugs Market Overview
• 15.2. Western Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Musculoskeletal Disorders Drugs Market

• 16.1. UK Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Musculoskeletal Disorders Drugs Market

• 17.1. Germany Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Musculoskeletal Disorders Drugs Market

• 18.1. France Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Musculoskeletal Disorders Drugs Market

• 19.1. Italy Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Musculoskeletal Disorders Drugs Market

• 20.1. Spain Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Musculoskeletal Disorders Drugs Market

• 21.1. Eastern Europe Generic Musculoskeletal Disorders Drugs Market Overview
• 21.2. Eastern Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Musculoskeletal Disorders Drugs Market

• 22.1. Russia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Musculoskeletal Disorders Drugs Market

• 23.1. North America Generic Musculoskeletal Disorders Drugs Market Overview
• 23.2. North America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Musculoskeletal Disorders Drugs Market

• 24.1. USA Generic Musculoskeletal Disorders Drugs Market Overview
• 24.2. USA Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Musculoskeletal Disorders Drugs Market

• 25.1. Canada Generic Musculoskeletal Disorders Drugs Market Overview
• 25.2. Canada Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Musculoskeletal Disorders Drugs Market

• 26.1. South America Generic Musculoskeletal Disorders Drugs Market Overview
• 26.2. South America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Musculoskeletal Disorders Drugs Market

• 27.1. Brazil Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Musculoskeletal Disorders Drugs Market

• 28.1. Middle East Generic Musculoskeletal Disorders Drugs Market Overview
• 28.2. Middle East Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Musculoskeletal Disorders Drugs Market

• 29.1. Africa Generic Musculoskeletal Disorders Drugs Market Overview
• 29.2. Africa Generic Musculoskeletal Disorders Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Generic Musculoskeletal Disorders Drugs Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Generic Musculoskeletal Disorders Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Musculoskeletal Disorders Drugs Market Competitive Landscape And Company Profiles

• 30.1. Generic Musculoskeletal Disorders Drugs Market Competitive Landscape
• 30.2. Generic Musculoskeletal Disorders Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ampio Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Generic Musculoskeletal Disorders Drugs Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Merck & Co. Inc.
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Teva Pharmaceuticals Industries Ltd.
• 31.5. AstraZeneca plc
• 31.6. Mitsubishi Tanabe Pharma Corporation
• 31.7. Horizon Therapeutics plc
• 31.8. Eisai Co. Ltd.
• 31.9. Biogen Inc.
• 31.10. Sino Biopharmaceutical Limited
• 31.11. Bristol-Myers Squibb Company
• 31.12. Johnson & Johnson Services Inc.
• 31.13. AbbVie Inc.
• 31.14. Novartis AG
• 31.15. F. Hoffmann-La Roche Ltd.

32. Global Generic Musculoskeletal Disorders Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Musculoskeletal Disorders Drugs Market

34. Recent Developments In The Generic Musculoskeletal Disorders Drugs Market

35. Generic Musculoskeletal Disorders Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Generic Musculoskeletal Disorders Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Generic Musculoskeletal Disorders Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Generic Musculoskeletal Disorders Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer